



MEMORANDUM

Date: April 27, 2023

From: Varsha Garnepudi, MS
Division of Biological Standards and Quality Control (DBSQC)
Office of Compliance and Biologics Quality (OCBQ)
Center for Biologics Evaluation and Research (CBER)
Food and Drug Administration (FDA)

To: Biologics License Application Submission Tracking Number 125774

Subject: Lot Release Protocol Template (LRP) for beremagene geperpavec, B-VEC/KB103 VYJUVEK™ for the treatment of wounds for patients over 6 months of age with dystrophic epidermolysis bullosa (DEB)

Through: Maryna Eichelberger, PhD, Director DBSQC/OCBQ/CBER/FDA

Cc: Anna Kwilas, PhD, Chair, GTB5/DGT2/OGT/OTP/CBER/FDA
Rommel Maglalang, PhD, RPM, DRMRR2/ORMRR/OTP/CBER/FDA
Marie Anderson, PhD, DBSQC/OCBQ/CBER/FDA

Applicant: Krystal Biotech, Inc

Product: beremagene geperpavec, B-VEC/KB103-

Trade Name: VYJUVEK™

Summary: The LRP template for beremagene geperpavec, B-VEC/KB103 VYJUVEK™ submitted in amendment 125774/0.55 on March 28, 2023, is acceptable for use.

1 General Information

1.1 CMC Review Identifiers and Dates

1.1.1 Biologics License Application (BLA) Submission Tracking Number (STN): 125774

1.1.2 Submission received by CBER: June 02, 2022

1.1.3 Review completed: March 28, 2023

1.1.4 Material Reviewed: BLA 125774

1.1.5 Related Master File, INDs and BLAs: BLA 125774

2 Review

2.1 Documents Reviewed

LRP template for beremagene geperpavec, B-VEC/KB103 VYJUVEK™ submitted on December 06, 2022, in BLA 125774/0.35

Response and revised LRP template for beremagene geperpavec, B-VEC/KB103 VYJUVEK™ submitted on February 07, 2023, in amendment BLA 125774/0.44

Response and revised LRP template for beremagene geperpavec, B-VEC/KB103 VYJUVEK™ submitted on March 17, 2023, in amendment BLA 125774/0.53.

Response and revised LRP template for beremagene geperpavec, B-VEC/KB103 VYJUVEK™ submitted on March 28, 2023, in amendment BLA 125774/0.55

2.2 Review

A LRP template was not submitted by Krystal in BLA 125774/0 on September 02, 2022. An IR was sent to Krystal on October 5, 2022, to submit a LRP template that includes the release specifications for the drug substance and drug product along with the test parameter, method type, and acceptance criteria.

A response and LRP template were submitted in amendment 125774/0.35 on December 06, 2022. This template was reviewed by OGT/DGT2/GTB5 OCBQ/DMPQ/PRB, and OCBQ/DBSQC with comments from GTB5, PRB and DBSQC.

An IR was sent to Krystal on January 24, 2023, to submit a revised LRP template to include several formatting changes as well as additional information for (b) (4) and endotoxin testing. In addition, information was provided regarding launch lots and the mechanism to submit LRPs. Templates were provided for (b) (4) assay, eLRP signature letter, Electronic Protocol page 1 and sample submission form.

A response and revised LRP template were submitted in amendment 125774/0.44 on February 7, 2023. This template was reviewed by OGT/DGT2/GTB5, OCBQ/DMPQ/PRB, and OCBQ/DBSQC with comments from GTB5, PRB and DBSQC.

An IR was sent to Krystal on March 14, 2023, to submit a revised LRP template to include several formatting changes, updated specifications for a few tests and to correct some assay validity and acceptance criteria.

A response and LRP template were submitted in amendment 125774/0.53 on March 17, 2023. This template was reviewed by OGT/DGT2/GTB5, OCBQ/DMPQ/PRB, and OCBQ/DBSQC with comments from DBSQC.

An IR was sent to Krystal on March 27, 2023, to submit a revised LRP template to correct the (b) (4) assay acceptance criteria.

The updated template was submitted in amendment 125774/0.55 on March 28, 2023. This template was reviewed by OCBQ/DBSQC with no additional comments.

3 Conclusions

The LRP template for beremagene geperpavec, B-VEC/KB103 VYJUVEK™ submitted in amendment 125774/0.55 on March 28, 2023, is acceptable for use. This template may be used for future lot release submissions. To prepare to review LRPs submitted to CBER, a testing plan and LRP routing slip are being developed.